New Zealand markets closed
  • NZX 50

    13,093.24
    -32.76 (-0.25%)
     
  • NZD/USD

    0.7169
    +0.0011 (+0.16%)
     
  • NZD/EUR

    0.6141
    +0.0004 (+0.07%)
     
  • ALL ORDS

    7,761.00
    +34.20 (+0.44%)
     
  • ASX 200

    7,449.50
    +34.00 (+0.46%)
     
  • OIL

    84.61
    +0.85 (+1.01%)
     
  • GOLD

    1,799.70
    +3.40 (+0.19%)
     
  • NASDAQ

    15,355.07
    -134.53 (-0.87%)
     
  • FTSE

    7,204.55
    +14.25 (+0.20%)
     
  • Dow Jones

    35,677.02
    +73.92 (+0.21%)
     
  • DAX

    15,542.98
    +70.38 (+0.45%)
     
  • Hang Seng

    26,157.35
    +30.42 (+0.12%)
     
  • NIKKEI 225

    28,575.86
    -228.99 (-0.79%)
     
  • NZD/JPY

    81.4000
    +0.2140 (+0.26%)
     

Royalty Pharma to Present at Upcoming Investor Conferences

·1-min read

NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

  • Citi’s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m. EDT

  • Morgan Stanley’s 19th Annual Global Healthcare Conference on Tuesday, September 14 at 11:00 a.m. EDT

The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting